Aspire Biopharma Holdings (ASBP) Notes Payables (2021 - 2025)

Aspire Biopharma Holdings (ASBP) has 3 years of Notes Payables data on file, last reported at $40954.0 in Q4 2025.

• On a quarterly basis, Notes Payables fell 95.55% year-over-year to $40954.0 in Q4 2025; TTM through Dec 2025 was $40954.0, a 95.55% decrease from a year earlier, with the FY2025 full-year figure at $40954.0, down 95.55% from the prior year.
• Notes Payables for Q4 2025 stood at $40954.0, down from $3.6 million in the prior quarter.
• Over the last five years, Notes Payables for ASBP reached as high as $3.6 million in Q3 2025 and fell as low as $40954.0 in Q4 2025.
• Historically, Notes Payables has averaged $1.2 million across 3 years, with a median of $1.1 million in 2024.
• On a YoY basis, Notes Payables climbed as much as 95.55% in 2025 and fell as far as 95.55% in 2025.
• Year by year, Notes Payables stood at $238596.0 in 2021, then jumped by 285.69% to $920240.0 in 2024, then plunged by 95.55% to $40954.0 in 2025.
• Per Business Quant data, the three most recent Notes Payables figures were $40954.0 in Q4 2025, $3.6 million in Q3 2025, and $1.3 million in Q2 2025.